Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 13, 2003 - Issue 2
Submit an article Journal homepage
51
Views
10
CrossRef citations to date
0
Altmetric
Review

Inhibitors of vascular cell adhesion molecule-1 expression

Erwin P Schreiner Novartis Forschungsinstitut, Brunner Strasse 59, A-1235 Vienna, Austria. [email protected]
,
Berndt Oberhauser Novartis Forschungsinstitut, Brunner Strasse 59, A-1235 Vienna, Austria. [email protected]
&
Carolyn A Foster Novartis Forschungsinstitut, Brunner Strasse 59, A-1235 Vienna, Austria. [email protected]
Pages 149-166 | Published online: 02 Mar 2005

Bibliography

  • VON ANDRIAN UH, MACKAY CR: T-cell function and migration - two sides of the same coin. N Engl. Med. (2000) 343:1020–1034.
  • ••Excellent review covering the principles ofleukocye (expecially T cell) trafficking, including key pioneering work as well as recent cutting-edge papers.
  • ALON R, FEIGELSON S: From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin. Immunol (2002) 14:93–104.
  • LAUDANNA C, KIM JY, CONSTANTIN G, BUTCHER E: Rapid leukocyte integrin activation by chemokines. Immunol Rev (2002) 186:37–46.
  • PAPAYANNOPOULOU T, PRIESTLEY GV, NAKAMOTO B, ZAFIROPOULOS V, SCOTT LM: Molecular pathways in bone marrow homing: dominant role of a431 over 132-integrins and selectins. Blood (2001) 98:2403–2411.
  • •Compelling evidence that the VLA-4/ VCAM-1 pathway alone, in the absence of 132 integrins or selectins, can effectively capture haematopoietic cells within the bone marrow.
  • SAXENA U, MEDFORD RM: Vascular adhesion molecule-1 (VCAM-1), an inflammatory gene target for new therapeutics. Curl: Opin. Cardiovasc. Palm. Rena] Invest. Drugs (2000) 2:258–262.
  • CARTER RA, WICKS IP: Vascular cell adhesion molecule 1 (CD106): a multifaceted regulator of joint inflammation. Arthritic Rheum. (2001) 44:985–994.
  • HICKEY MJ, GRANGER DN, KUBES P: Molecular mechanisms underlying IL-4-induced leukocyte recruitment in vivo: a critical role for the a4 integrin. Immunol (1999) 163:3441–3448.
  • BAGGIOLINI M: Chemokines in pathology and medicine. Intern. Med. (2001) 250:91–104.
  • OLSON TS, LEY K: Chemokines and chemokine receptors in leukocyte trafficking. Am. j Physiol Regal Integr: Comp. Physiol (2002) 283:R7–R28.
  • •Up-to-date and comprehensive review regarding the role of chemokines and their receptors in leukocyte recruitment.
  • JOHNSTON B, KUBES P: The a4-integrin: an alternative pathway for neutrophil recruitment? Immunol Today (1999) 20:545–550.
  • IBBOTSON GC, DOIG C, KAURJ et al: Functional a4-integrin: a newly identified pathway of neutrophil recruitment in critically ill septic patients. Nat. Med. (2001) 7:465–470.
  • •First description of neutrophil recruitment in human disease mediated by the VLA-4/ VCAM-1 pathway.
  • BOWDEN RA, DING Z-M, DONNACHIE EM et al.: Role of a4 integrin and VCAM-1 in CD18-independent neutrophil migration across mouse cardiac endothelium. Circ. Res. (2002) 90:562–569.
  • TAO OKA Y, CHEN J, YEDNOCK T, SHEPPARD D: The integrin a9131 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1. J. Cell Biol. (1999) 145:413–420.
  • VAN DER VIEREN M, CROWE DT, HOEKSTRA D et al.: The leukocyte integrin aD32 binds VCAM- 1: evidence for a binding interface between I domain and VCAM-1. I Immunol (1999) 163:1984–1990.
  • ROTT LS, BRISKIN MJ, BUTCHER EC:Expression of a437 and E-selectin ligand by circulating memory B cells: implications for targeted trafficking to mucosal and systemic sites. Leukoc. Biol. (2000) 68:807–814.
  • ROSE DM, GRABOVSKY V, ALON R, GINSBERG MH: The affinity of integrin c(4131 governs lymphocyte migration. Immunol (2001) 167:2824–2830.
  • NEISH AS, AGGARWAL S, COLLINS T: Transcriptional regulation of VCAM-1. In: Leukocyte recruitment, endothelial cell adhesion molecular, and transcriptional control. Collins T (Ed.), Kluwer Academic Publishers, Boston (2001):175–201.
  • YUSUF-MAKAGIANSAR H, ANDERSON ME, YAKOVLEVA TV, MURRAY JS, SIAHAAN TJ: Inhibition of LFA-1/ICAM-1 and VLA-4NCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev (2002) 22:146–167.
  • KITANI A, NAKASHIMA N, IZUMIHARA T et al.: Soluble VCAM-1 induces chemotaxis of Jurkat and synovial fluid T cells bearing high affinity very late antigen-4. f Immunol (1998) 161:4931–4938.
  • FUKUSHI J, ONO M, MORIKAWA W, IWAMOTO Y, KUVVANO M: The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. f Immunol (2000) 165:2818–2823.
  • ROSE DM, CARDARELLI PM, COBB RR, GINSBERG MH: Soluble VCAM-1 binding to a4integrins is cell-type specific and activation dependent and is disrupted during apoptosis in T cells. Blood (2000) 95:602–609.
  • TOKUHIRA M, HOSAKA S, VOLIN MV et al.: Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritic Rheum. (2000) 43:1122–1133.
  • BYRNE GJ, GHELLAL A, IDDON J et al.: Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. Natl. Cancer Inst. (2000) 92:1329–1336.
  • KOLOPP-SARDA MN, GUILLEMIN F, CHARY-VALCKENAERE I, BENE MC, POUREL J, FAURE GC: Longitudinal study of rheumatoid arthritis patients discloses sustained elevated serum levels of soluble CD106 (V-CAM). Clin. Exp. Rheumatol (2001) 19:165–170.
  • WRIGHT PS, COOPER JR, KROPP KE, BUSCH SJ: Induction of vascular cell adhesion molecule-1 expression by IL-4 in human aortic smooth muscle cells is not associated with increased nuclear NF-icB levels. Cell Physiol (1999) 180:381–389.
  • DE CATERINA R, BOURCIER T, LAUFS U et al.: Induction of endothelial-leukocyte interaction by interferon-y requires coactivation of nuclear factor-KB. Arterioscler: Thromb. Vasc. Biol. (2001) 21:227–232.
  • JESSE TL, LACHANCE R, IADEMARCO ME DEAN DC: Interferon regulatory factor-2 is a transcriptional activator in muscle where it regulates expression of vascular cell adhesion molecule-1. f Cell Biol. (1998) 140:1265–1276.
  • HAWKE TJ, GARRY DJ: Myogenic satellite cells: physiology to molecular biology. Appl. Physiol (2001) 91:534–551.
  • MINAMI T, AIRD WC: Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-icB and GATA motifs. f. Biol. Chem. (2001) 276:47632–47641.
  • UMETANI M, MATAKI C, MINEGISHI N, YAMAMOTO M, HAMAKUBO T, KODAMA T: Function of GATA transcription factors in induction of endothelial vascular cell adhesion molecule-1 by tumor necrosis factor-a. Arterioscler. Thromb. Vase. Biol. (2001) 21:917–922.
  • LEE YW, KOHN H, HENNIG B, NEISH AS, TOBOREK M: IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J. MM. Cardiol (2001) 33:83–94.
  • •Further evidence that IL-4 mediated VCAM-1 expression is NF-x13 independent, following 1995 observations by McCarty etal. WEBS Lett. 372:194-98), and that cytokine activation of NF-x13 depends on specific signal transduction mechanisms rather than ubiquitously induced cellular oxidative stress.
  • LOBB RR, ABRAHAM WM, BURKLY LC et at Pathophysiologic role of a4integrins in the lung. Ann. N Y Acad. Sci. (1996) 796:113–123.
  • JACKSON DY: Alpha 4 integrin antagonists. Carr. Amin. Des. (2002) 8:1229–1253.
  • KUDLACZ E, WHITNEY C, ANDRESEN C et al: Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule a4I31 antagonists. " Pharmacol Exp. Ther: (2002) 301:747–752.
  • MOUSA SA: Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Carr: Opin. Chem. Biol. (2002) 6:534–541.
  • SINGH J, VAN VLIJMEN H, LIAO Y et al.: Identification of potent and novel a4 pi antagonists using in silico screening. J. Med. Chem. (2002) 45:2988–2993.
  • TILLEY JW: VLA-4 antagonists. Expert Opin. Ther. Patents (2002) 12:991–1008.
  • ••Up-to-date patent review of VLA-4antagonists in the pipeline.
  • LIU G: Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents. Expert Opin. Ther. Patents (2001) 11:1383–1393.
  • DOWNS KM: Early placental ontogeny in the mouse. Placenta (2002) 23:116–131.
  • KONI PA, JOSHI SK, TEMANN U-A, OLSON D, BURKLY L, FLAVELL RA: Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. I Exp. Med. (2001) 193:741–753.
  • •Valuable new animal models due to the generation of VCAM-1 knock-in and transgenic mice, thus overcoming the embryonic lethality seen in conventional VCAM-1 deficiency (Genes Dev. (1995) 1:1-14; Development (1995) 2:489–503).
  • LEUKER CE, LABOW M, MOLLER W, WAGNER N: Neonatally induced inactivation of the vascular cell adhesion molecule 1 gene impairs B cell localization and T cell-dependent humoral immune response.j Exp. Med. (2001) 193:755–767.
  • •Similar contribution as for [40], also by generating conditional VCAM-1 mutant mice.
  • ROSS R: Atherosclerosis - an inflammatory disease. N Engl. J. Med. (1999) 340:115–126.
  • ••Elegant and controversial position paper,arguing in part that atherogenesis is an inflammatory response to modified lipoproteins trapped in the arterial wall.
  • KUNSCH C, MEDFORD RM: Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res. (1999) 85:753–766.
  • •Review of evidence that oxidative stress is a major risk factor in atherosderosis.
  • COLLINS T, CYBULSKY MI: NF-icB: pivotal mediator or innocent bystander in atherogenesis?" Clin. Invest. (2001) 107:255–264.
  • •Provocative assessment of NF-x13 role in atherosclerosis.
  • WITZTUM JL, STEINBERG D: The oxidative modification hypothesis of atherosclerosis; does it hold for humans? Trends Cardiovasc. Med. (2001) 11:93–102.
  • •Review supporting the key role of LDL oxidation in atherogenesis.
  • FRUEBIS J, GONZALEZ V, SILVESTRE M, PALINSKI W: Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler: Thromb. Vase. Biol. (1997) 17:1289–1302.
  • TRUSKEY GA, HERRMANN RA, KAIT J, BARBER KM: Focal increases in vascular cell adhesion molecule-1 and intimal macrophages at atherosclerosis-susceptible sites in the rabbit aorta after short-term cholesterol feeding. Arterioscler. Thromb. Vase. Biol. (1999) 19:393–401.
  • AIKAWA M, SUGIYAMA S, HILL CC et at Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation (2002) 106:1390–1396.
  • CYBULSKY MI, IIYAMA K, LI H et al: A major role for VCAM-1, but not I CAM-1, in early atherosclerosis. J. Clin. Invest. (2001) 107:1255–1262.
  • ••Study shows for the first time that VCAM-1is critical for the development of atherosclerotic lesions, utilising mice with the LDL receptor-null background and deficient in VCAM-1 domain 4.
  • DANSKY HM, BARLOW CB, LOMINSKA C et al.: Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler: Thromb. Vase. Biol. (2001) 21:1662–1667.
  • TARDIF J-C, COTE G, LESPERANCE Jet al.: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl. I Med. (1997) 337:365–372.
  • OKAMOTO E, COUSE T, DE LEON H et al.: Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation (2001) 104:2228–2235.
  • OGUCHI S, DIMAYUGA P, ZHU Jet al.:Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. ArteriOSCIer. Thromb. Vase. Biol. (2000) 20:1729–1736.
  • HUO Y, HAFEZI-MOGHADAM A, LEY K: Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ. Res. (2000) 87:153–159.
  • BARNES KC: Evidence for common genetic elements in allergic disease. I Allergy Clin. Immunol (2000) 106:5192–5200.
  • TERREEHORST I, OOSTING AJ, TEMPELS-PAVLICA Z et al.: Prevalence and severity of allergic rhinitis in house dust mite-allergic patients with bronchial asthma or atopic dermatitis. Clin. Exp. Allergy(2002) 32:1160–1165.
  • CONROY DM, WILLIAMS TJ: Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir. Res. (2001) 2:150–156.
  • RIFFO-VASQUEZ Y, SPINA D: Role of cytokines and chemokines in bronchial hyperresponsiveness and airway inflammation. Pharmacol Ther: (2002) 94:185–211.
  • TEMANN U-A, RAY P, FLAVELL RA: Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J. Clin. Invest. (2002) 109:29–39.
  • WALTER DM, MCINTIRE JJ, BERRY G et al.: Critical role for IL-13 in the development of allergen-induced airway hyperreactivity." Immunol (2001) 167:4668–4675.
  • FALCONE FH, HAAS H, GIBBS BF: The human basophil: a new appreciation of its role in immune responses. Blood (2000) 96:4028–4038.
  • PAGE S, AMMIT AJ, BLACK JL, ARMOUR CL: Human mast cell and airway smooth muscle cell interactions: implications for asthma. Am. I Physiol. Lung Cell Ma Physiol. (2001) 281:L1313–L1323.
  • BOONE M, LESPAGNARD L, RENARD N, SONG M, RIHOUX JP: Adhesion molecule profiles in atopic dermatitis vs. allergic contact dermatitis: pharmacological modulation by cetirizine. Eur. Acad. Dermatol Venereol (2000) 14:263–266.
  • BRAUNSTAHL G-J, OVERBEEK SE, KLEINJAN A, PRINS J-B, HOOGSTEDEN HC, FOKKENS WJ: Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. I Allergy Clin. Immunol (2001) 107:469–476.
  • WILSON SJ, WALLIN A, DELLA-CIOPPA G, SANDSTROM T, HOLGATE ST: Effects of budesonide and formoterol on NF-icB, adhesion molecules, and cytokines in asthma. Am. I Respic Grit. Care Med. (2001) 164:1047–1052.
  • FOSTER CA: VCAM-1/a4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders. J. Allergy Clin. Immunol (1996) 98:S270–277.
  • NAGAI K, LARKIN S, HARTNELL A et al.: Human eotaxin induces eosinophil extravasation through rat mesenteric venules: role of a4 integrins and vascular cell adhesion molecule-1. Immunology (1999) 96:176–183.
  • KAMINUMA O, FUJIMURA H, FUSHIMI K et al.: Dynamics of antigen-specific helper T cells at the initiation of airway eosinophilic inflammation. Euc Immunol (2001) 31:2669–2679.
  • WANG S, FAN Y, HAN X, YANG J, BILENKI L, YANG X: IL-12-dependent vascular cell adhesion molecule-1 expression contributes to airway eosinophilic inflammation in a mouse model of asthma-like reaction. Immunol (2001) 166:2741–2749.
  • •Recent study in IL-12 knockout mice highlighting the importance of VCAM-1 in promoting circulating eosinophil migration into airways.
  • BOLGER GT: Bio-1211 (Biogen). Curr. Opin. Anti-In/lam. Immunomod. Invest. Drugs (2000) 2:108–112.
  • PODOLSKY DK: Inflammatory bowel disease. N Engl. J. Med. (2002) 347:417–429.
  • •Up-to-date review of the etiology, pathophysiology and treatment of IBD, including status of investigational agents.
  • SORIANO A, SALAS A, SALAS A et al.: VCAM-1, but not I CAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab. Invest. (2000) 80:1541–1551.
  • BURNS RC, RIVERA-NIEVES J, MOSKALUK CA, MATSUMOTO S, COMINELLI F, LEY K: Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/ Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology (2001) 121:1428–1436.
  • RIJCKEN E, KRIEGLSTEIN CE ANTHONI C et al: ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease. Gut (2002) 51:529–535.
  • GORDON FH, HAMILTON MI, DONOGHUE S et al: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Ailment. Pbarmacol Tber. (2002) 16:699–705.
  • •UK group reports first results of anti-a4 integrin antibody natalizumab in ulcerative colitis, also citing their clinical studies in Crohn's disease.
  • HEMMER B, ARCHELOS JJ, HARTUNG HP: New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. (2002) 3:291–301.
  • ••Recent insightful review on the pathogenesis of MS and the outlook for new therapeutic strategies.
  • FLOGEL A, BERKOWICZ T, RITTER T et al: Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity (2001) 14:547–560.
  • VAJKOCZY P, LASCHINGER M, ENGELHARDT B: acintegrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. I Clin. Invest. (2001) 108:557–565.
  • •Elegant intravital fluorescence videomicroscopy study providing the first direct in vivo evidence that VCAM-1 may function as a CNS-specific addressin.
  • PIRAINO PS, YEDNOCK TA, FREEDMAN SB et al: Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of a4 integrin. Neurnimmunol (2001) 131:147–159.
  • TUBRIDY N, BEHAN PO, CAPILDEO R et al.: The effect of anti-a4 integrin antibody on brain lesion activity in MS. Neurology (1999) 53:466–472.
  • •Report of first clinical studies using anti-a4 integrin antibody in MS patients.
  • SMITH JB, HAYNES MK: Rheumatoid arthritis - a molecular understanding. Ann. Intern. Med. (2002) 136:908–922.
  • LI P, SANZ I, O'KEEFE RJ, SCHWARZ EM: NF-icB regulates VCAM-1 expression on fibroblast-like synoviocytes. Immunol (2000) 164:5990–5997.
  • ISSEKUTZ TB, MIYASAKA M, ISSEKUTZ AC: Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation. J. Exp. Med. (1996) 183:2175–2184.
  • CARTER RA, CAMPBELL IK, O'DONNELL K, WICKS IP: Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking. Clin. Exp. Immunol (2002) 128:44–51.
  • KRAAN MC, REECE RJ, BARG EC et al.: Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum. (2000) 43:1820–1830.
  • SMITH MD, SLAVOTINEK J, AU V et al: Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression. Rbeumatology (2001) 40:965–977.
  • CASCALHO M, PLATT JL: The immunological barrier to xenotransplantation. Immunity (2001) 14:437–446.
  • STE GALL MD, DEAN PG, NINOVA D et al.: a4 integrin in islet allograft rejection. Transplantation (2001) 71:1549–1555.
  • ISOBE M, HORI J, SUZUKI J: Immunosuppression by blocking a4-integrinsNCAM-1 adhesion. Curc Top. Microbiol Immunol (1998) 231:85–98.
  • ALLEN AR, MCHALE J, SMITH J et al.: Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury. I Immunol (1999) 162:5519–5527.
  • JOHNSTON B, CHEE A, ISSEKUTZ TB et al.: a4 integrin-dependent leukocyte recruitment does not require VCAM-1 in a chronic model of inflammation. Immunol (2000) 164:3337–3344.
  • LARBI KY, ALLEN AR, TAM FVVK et al: VCAM-1 has a tissue-specific role in mediating interleukin-4-induced eosinophil accumulation in rat models: evidence for a dissociation between endothelial-cell VCAM-1 expression and a functional role in eosinophil migration. Blood(2000) 96:3601–3609.
  • OPALINSKA JB, GEWIRTZ AM: Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev Drug Discov. (2002) 1:503–514.
  • BENNETT CF, CONDON TP, GRIMM S, CHAN H, CHIANG M-Y: Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. Immunol (1994) 152:3530–3540.
  • MUELLER JP, GIANNONI MA, HARTMAN SL et al.: Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Ma Immunol (1997) 34:441–452.
  • ROSES AD: Genome-based pharmacogenetics and the pharmaceutical industry. Nat. Rev Drug Discov. (2002) 1:541–549.
  • DROGE W: Free radicals in the physiological control of cell function. Physiol Rev (2002) 82:47–95.
  • •Broad overview, in textbook style, summarising the main principles of redox regulation.
  • HENRICKS PAJ, NIJKAMP FP: Reactive oxygen species as mediators in asthma. Palm. Pharmacol The]: (2001) 14:409–421.
  • FRUEBIS J, SILVESTRE M, SHELTON D,NAPOLI C, PALINSKI W: Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits. .1 Lipid Res. (1999) 40:1958–1966.
  • SOMERS PK, MEDFORD RM, SAXENA U: Dithiocarbamates: effects on lipid hydroperwddes and vascular inflammatory gene expression. Free Radic. Biol. Med. (2000) 28:1532–1537.
  • BOWIE AG, MOYNAGH PN, O'NEILL LAJ: Lipid peroxidation is involved in the activation of NF-icB by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304. Biol. Chem. (1997) 272:25941–25950.
  • LI N, KARIN M: Is NF-icB the sensor of oxidative stress? FASEB J. (1999) 13:1137–1143.
  • TUMMALA PE, CHEN X-L, MEDFORD RM: NF-icB independent suppression of endothelial vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 gene expression by inhibition of flavin binding proteins and superoxide production. I Mol Cell Cardiol (2000) 32:1499–1508.
  • KHAN By, PARTHASARATHY SS, ALEXANDER RW, MEDFORD RM: Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J. Clin. Invest. (1995) 95:1262–1270.
  • •Fundamental paper showing the potential for oxLDL and its components to act as an oxidative signal that augments redox-sensitive endothelial VCAM-1 expression. More recently, AtheroGenics identified a unique antioxidant response element (j Biol. Chem. (2003) 278:703–711).
  • MENG CQ, SOMERS PK, RACHITA CL et al.: Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg. Med. Chem. Lett. (2002) 12:2545–2548.
  • •Paper describing medicinal chemistry studies resulting in lead AGI-1067.
  • NAKAMURA R, EGASHIRA K, MACHIDA Y et al.: Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: Roles of oxidative stress and inflammation. Circulation (2002) 106:362–367.
  • ELINDER LS, HADELL K, JOHANSSON J et al.: Probucol treatment decreases serum concentrations of diet-derived antioxidants. Arteriosclei: Thromb. Vasc. Biol. (1995) 15:1057–1063.
  • MENG C, SOMERS P, RACHITA C, HOONG L, HILL R, SUNDELL C: Novel phenolic antioxidants as multifunctional inhibitors of VCAM-1 expression for coronary artery disease. 223rd ACS National Meeting Orlando, USA (2002). MEDI–122.
  • HATCH GM: AGI-1067 AthetoGenics. Carr: Opin. Livestig. Drugs (2002) 3:433–436.
  • CAMPBELL WB: New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol ScL (2000) 21:125–127.
  • HOMMEL U, WEBER H-P, OBERER L, NAEGELI HU, OBERHAUSER B, FOSTER CA: The 3D-structure of a natural inhibitor of cell adhesion molecule expression. FEBS Lett. (1996) 379:69–73.
  • BOGER DL, KEIM H, OBERHAUSER B, SCHREINER EP, FOSTER CA: Total synthesis of HUN-7293. I Am. Chem. Soc. (1999) 121:6197–6205.
  • FOSTER CA, DREYFUSS M, MANDAK B et al.: Pharmacological modulation of endothelial cell-associated adhesion molecule expression: implications for future treatment of dermatological diseases. " Dermatol (1994) 21:847–854.
  • FOSTER CA, BESEMERJ, MEINGASSNER JG et al.: Novel inhibitor of endothelial cell-associated VCAM-1. Skin Pharmacol (1996) 9:149.
  • LIANG X, ANDO A, TAKAHASHI K et al: An inhibitor of VCAM-1 decreases retinal neovascularization and capillary nonperfusion in a model of ischemic retinopathy. Invest. Ophthalmol Vis. Sci. (2001) 42:S89.
  • CHEN Y, BILBAN M, FOSTER CA, BOGER DL: Solution-phase parallel synthesis of a pharmacophore library of HUN-7293 analogues: a general chemical mutagenesis approach to defining structure-function properties of naturally occurring cyclic (depsi)peptides. I Am. Chem. Soc. (2002) 124:5431–5440.
  • •Paper reporting the first SAR information for HUN-7293 analogues.
  • SCHREINER EP, KERN M, STECK A: A convenient protocol for selective cleavage of 2-hydroxy acid amides. Application to semisynthesis of the cyclic heptapeptide aza HUN-7293.j Org. Chem. (2002) 67:8299–8304.
  • BOGER DL, CHEN Y, FOSTER CA: Synthesis and evaluation of aza HUN-7293. Bioorg. Med. Chem. Lett. (2000) 10:1741–1744.
  • SCHREINER EP, GODIN G, BROUTIN P-E, FOSTER CA: Design and synthesis of cyclophanes related to the VCAM-1 expression inhibitor HUN-7293. 222nd ACS National Meeting. Chicago, USA (2001) MEDI–131.
  • WANG S, WINISKI AP, SCHEEL G et al.: Discovery of two new natural products in a high-throughput assay: potent inhibition of VCAM-1 expression by distinctly different mechanisms. Mol Biol. Cell (2000) 11:467a.
  • WOLLE J, HILL RR, FERGUSON E et al.: Selective inhibition of tumor necrosis factor-induced vascular cell adhesion molecule-1 gene expression by a novel flavonoid. Lack of effect on transcription factor NF-icB. Arteriosclec Thromb. Vase. Biol. (1996) 16:1501–1508.
  • DIMMOCK JR, ELIAS DW, BEAZELY MA, KANDEPU NM: Bioactivities of chalcones. Can: Med. Chem. (1999) 6:1125–1149.
  • •Comprehensive overview of biologically active chalcones.
  • ZHU G-D, SCHAEFER V, BOYD SA, OKASINSKI GF: Synthesis and mode of action of 1251- and 3H-labeled thieno[2,3-dpyridine antagonists of cell adhesion molecule expression.' Org. Chem. (2002) 67:943–948.
  • WALKER G, LANGHEINRICH AC, DENNHAUSER E et al: 3-Deazaadenosine prevents adhesion molecule expression and atherosclerotic lesion formation in the aortas of C57BL/6J mice. Arterioscler. Thromb. Vase. Biol. (1999) 19:2673–2679.
  • AHMAD M, ZHANG Y, ZHANG Y, PAPHARALAMBUS C, ALEXANDER RW: Role of isoprenylcysteine carboxyl methyltransferase in tumor necrosis factor-a stimulation of expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler. Thromb. Vase. Biol. (2002) 22:759–764.
  • LIM LHK, BO CHNER BS, WAGNER EM: Leukocyte recruitment in the airways: an intravital microscopic study of rat tracheal microcirculation. Am. I Physic] Lung Cell. Mel Physic] (2002) 282:L959–L967.

Websites

  • •First paper using intravital microscopy to study inflammation in the airway circulation.
  • http://www.biogen.com Biogen corporate website.
  • http://www.isp.com ISIS Pharmaceuticals corporate website.
  • http://www.antisense.com.au/d1/89.pdf Antisense Therapeutics Limited, Dec 2001 market analysis website.
  • http://www.mc.vanderbilt.edu/cancer Vanderbilt-Ingram Cancer Center website.
  • http://www.atherogenics.com AtheroGenic press release.
  • http://www.aventis.com Aventis corporate website.
  • http://www.gsk.com GlaxoSmithKline corporate website.
  • http://wwwxenogen.com Xenogen corporate website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.